Ascendiant Capital Markets Reiterates “Buy” Rating for Vivos Therapeutics (NASDAQ:VVOS)

Ascendiant Capital Markets reaffirmed their buy rating on shares of Vivos Therapeutics (NASDAQ:VVOS) in a research note published on Wednesday,Benzinga reports. The firm currently has a $6.60 price target on the stock.

Separately, Alliance Global Partners cut their price target on shares of Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating for the company in a report on Tuesday.

Vivos Therapeutics Stock Performance

Shares of Vivos Therapeutics stock opened at $2.89 on Wednesday. Vivos Therapeutics has a one year low of $1.91 and a one year high of $48.79. The firm has a fifty day moving average of $2.78 and a two-hundred day moving average of $2.52.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.